Drug intelligence / Profile preview

Zolpel-Beta

Development stage: Unknown
Lead developer: Intra Life
Modality: Small Molecules
Administration: Oral

Overview

**Zolpel-Beta** is an oral fixed-dose tablet marketed by Intra Life containing etizolam 0.5 mg and propranolol 20 mg. Etizolam is a thienodiazepine anxiolytic that positively modulates gamma-aminobutyric acid type A receptors, while propranolol is a non-selective beta-adrenergic receptor antagonist that reduces adrenergic manifestations such as palpitations, tremor, and tachycardia. The combination is marketed for anxiety and stress-related symptoms, including generalized anxiety disorder, performance anxiety, and anxiety-associated palpitations.

Brand names: Zolpel-Beta
Other names: etizolam + propranololetizolam + propranolol hydrochloride

Targets

GABAA (Gamma-aminobutyric acid receptor)ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on Zolpel-Beta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zolpel-Beta.

Explore the full profile